GlycoMimetics Cash Flow - Quarterly (NASDAQ:GLYC)

Add to My Stocks
$14.58 $0.67 (4.82%) GLYC stock closing price Sep 18, 2018 (Closing)

For analyzing any company like GlycoMimetics from an investment perspective, its important to check the cash flow statement. This statement shows details about the cash generated and spent during a particular quarter, while the other two statements give details about GlycoMimetics profits and GlycoMimetics debt. This statement can tell if a company is running out of money while still being profitable and is useful in GlycoMimetics stock analysis. GlycoMimetics had a negative net income cash flow of $-22.79M till this quarter of 2018 Q2. This report is very useful in measuring the short term viability of a company. GlycoMimetics had an outflow of $-23.27M from operating activities, $128.82M inflow due to financing activities, and $-0.04M outflow due to investing activities till 2018 Q2.

View and download details of GlycoMimetics cash flows for latest & last 40 quarters
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
Net Income Cash Flow
Depreciation Depletion Amortization Cash-Flow----------
Net Increase (Decrease) in Assets Liabilities-2.88M--0.51M-0.36M-1.05M-2.02M-1.07M-2.67M-2.27M-2.44M
Cash From (used in) Discontinued Operations----------
Other Adjustments Net2.27M1.11M3.76M2.79M1.83M-2.96M2.23M1.49M-
Net Cash from (used by) Operating Activities
Increase (Decrease) in Prop Plant And Equipment-0.04M-0.01M-0.29M-0.25M-0.22M-0.06M-0.7M-0.26M-0.04M-0.01M
Acquisition Disposition of Subsidiaires----------
Increase (Decrease) in Investments----------
Other Cash Inflow (Outflow) from Investment Activities----------
Net Cash from (used by) Investment Activities
Issuance (Purchase) of Equity Shares128.82M128.93M113.94M94.49M94.5M3.67M23.67M22.52M22.62M1.27M
Issuance (Repayment) of Debt Securities----------
Increase (Decrease) in Bank & Other Borrowings----------
Payment of Dividends & Other Cash Distributions----------
Other Cash from (used by) Financing Activities----------
Net Cash from (used by) Financing Activities
Effect of Exchange Rate Changes on Cash----------
Net Change in Cash & Cash Equivalents
Cash & Equivalents at Beginning of Year123.92M40.04M46.8M55.19M2.31M17.37M28.17M14.58M--
Cash & Equivalents at Year End229.43M242.63M123.92M112.87M119.14M34.59M40.04M45.28M53.08M38.83M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

GlycoMimetics stock comparison chart provides an easy way to compare the stock price with peers along with details of GlycoMimetics stock price history.
The statement of cash flows can be categorized into the following main sections:

  • GlycoMimetics saw a negative change in Net Change in Cash and Cash Equivalents of $105.51M till 2018 Q2. Apart from the GlycoMimetics stock price, this is one of the things an investor looks for, as it shows the net change in cash on hand for a company, compared to previous period.
  • Cash Flow from operating activities: This is the cash that the company receives from ongoing operations. GlycoMimetics lost $-23.27M cash from operations. It is important to check this to see where the company is getting its money from.
  • Cash from investing stood at a negative value of $-0.04M for GLYC stock. A company with surplus cash usually thinks of re-investing it in the form of buying fixed assests, or purchasing plant/ machinery which will help grow the business further. By looking at cash flow from investment activities one can check where the company is putting its cash.
  • Inflow of cash in the form of bank loans and shareholders equity, and outflow of cash because of dividend payments, share repurchase payments etc. come under financing activities. The cash generated from these activities was $128.82M for GlycoMimetics.

Key Financial Ratios For GlycoMimetics Cash Flow

FCF margin

Quarterly Cash Flow Statements For GlycoMimetics Inc Peers

bluebird bio cash flow, Emisphere Tech cash flow, SANGAMO THERAP cash flow